Dr. Chapa’s Clinical Pearls. NEW Clinical Practice Update (Aug 2024)
Jul 29, 2024
Discover groundbreaking advancements in the management of alloimmunized pregnancies. Learn about the newly updated ACOG guidelines that emphasize the role of paternal and fetal genotyping. Delve into the use of cell-free DNA testing as a non-invasive tool for fetal red blood cell antigen detection. This update illustrates how quickly the medical field evolves to enhance care for high-risk pregnancies!
AI Snips
Chapters
Transcript
Episode notes
Paternal Genotyping
- In cases of alloimmunization in pregnancy, first determine the paternal genotype to assess fetal risk.
- If the father is homozygous negative for the antigen, the fetus is not at risk.
Non-Invasive Fetal Genotyping
- Cell-free DNA (cfDNA) analysis from maternal plasma offers a reliable, non-invasive alternative to invasive procedures like amniocentesis or CVS for fetal genotyping.
- This method avoids risks and costs associated with invasive testing.
ACOG Recommendation
- ACOG recommends using cfDNA as an alternative for fetal RHD testing in alloimmunized pregnancies.
- This especially applies when patients decline invasive procedures like amniocentesis.